Brainstorm Cell Therapeutics Inc.
BCLI
$0.69
$0.00-0.29%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.25% | -20.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.62% | -20.44% | |||
| Operating Income | -9.62% | 20.44% | |||
| Income Before Tax | -15.57% | 27.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.57% | 27.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.57% | 27.45% | |||
| EBIT | -9.62% | 20.44% | |||
| EBITDA | -9.85% | 20.74% | |||
| EPS Basic | -15.11% | 43.20% | |||
| Normalized Basic EPS | -15.05% | 43.18% | |||
| EPS Diluted | -15.11% | 43.20% | |||
| Normalized Diluted EPS | -15.05% | 43.18% | |||
| Average Basic Shares Outstanding | 0.42% | 27.70% | |||
| Average Diluted Shares Outstanding | 0.42% | 27.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||